Getting a denial letter for Wegovy, Zepbound, or any other GLP-1 medication is frustrating, but it is not the end of the road. A denial is often a starting position, not a final answer. Whether an appeal succeeds depends heavily on why you were denied and how well your documentation answers that specific reason. The key is knowing which denial you got and responding to it directly.
Here is a step-by-step guide for what to do next.
Why Insurers Deny GLP-1 Medications
Most denials fall into one of four categories, and knowing which one you got changes everything about how you respond.
"Not medically necessary" is the most common denial language. It usually means your insurer doesn't think your documentation is strong enough, not that the medication is categorically excluded. This is the most appealable denial type. A good Letter of Medical Necessity from your doctor can often flip it.
"Not a covered benefit" or "formulary exclusion" is harder to fight. Some commercial plans simply exclude weight loss medications from coverage. Federal law also keeps every Medicare Part D plan from covering drugs used only for weight loss. The separate Medicare GLP-1 Bridge runs outside Part D and has no appeals process. You can still appeal on medical necessity grounds, but the external appeal, or a complaint to the right regulator (see below), may matter more here.
"Step therapy required" means your plan wants proof you tried a cheaper alternative first, whether that's a different medication, a supervised diet program, or something else specific to your plan. Find out exactly what the step therapy requires and work with your doctor to satisfy it before reapplying.
BMI or diagnosis criteria not met means the insurer's records show you don't qualify. This often happens when the documentation submitted with the initial prior authorization request was incomplete. Fix the documentation, not the facts.
A note on the diabetes-versus-obesity distinction: Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not weight loss. Insurers are much more likely to cover them with a diabetes diagnosis. Wegovy and Zepbound are approved specifically for weight management. If your diagnosis is obesity and your doctor prescribed Ozempic off-label, your insurer may deny it on that basis alone, not because the medication is excluded, but because the indication doesn't match the approval. See our breakdown of why this distinction matters.
Step 1: Read the Denial Letter Carefully
Before you do anything else, find the denial letter and read every word. You're looking for three things: the specific denial reason (there will be a code or a sentence explaining it), the deadline to file an internal appeal (generally at least 180 days from the denial date), and the instructions for how to appeal.
Save the letter. You'll need to reference it throughout the process, and anyone you complain to later will want to see it.
If the letter is unclear (and insurance denial letters often are), call the member services number on the back of your insurance card and ask them to explain the specific denial reason in plain language. Ask for the clinical criteria your plan uses for GLP-1 medications. They're required to provide this. Write down the date of the call, the name of the representative, and what they told you.
Step 2: Have Your Doctor Submit a Letter of Medical Necessity
A Letter of Medical Necessity (LMN) from your prescribing physician is the foundation of any GLP-1 appeal. If one wasn't submitted with the original prior authorization request, that may be exactly why you were denied. If one was submitted and the claim was still denied, the letter may need to be more specific.
A strong LMN for a GLP-1 medication should include:
- Your current BMI and how it has changed over time
- Any weight-related comorbidities (hypertension, sleep apnea, prediabetes, type 2 diabetes, high cholesterol, PCOS, or osteoarthritis all count)
- A documented history of prior weight loss attempts: diet programs, exercise interventions, behavioral therapy, other medications tried and why they failed or were discontinued
- The specific medication being requested, with the FDA-approved indication it's being prescribed for
- Clinical justification citing relevant trial data (the STEP trials for semaglutide, SURMOUNT-1 for tirzepatide) and why this medication is appropriate for your specific situation
- A statement about cardiovascular or metabolic risk reduction, especially if you have related conditions. The SELECT trial showed semaglutide reduced major cardiovascular events in patients with obesity and cardiovascular disease, which is now a coverage argument insurers take seriously
Clinics that specialize in GLP-1 medications write these letters regularly. If your primary care doctor submitted the original request and it was denied, it may be worth getting a second opinion from a weight loss specialist or an obesity medicine physician. The American Board of Obesity Medicine has a directory of board-certified obesity medicine physicians. A specialist's letter carries more clinical weight with an insurer's medical reviewer.
Step 3: File a Formal Internal Appeal
Under the Affordable Care Act, you have the right to an internal appeal with your insurer. You generally have at least 180 days from receiving the denial notice to file (check your letter for the exact date). The insurer must respond within 30 days for services you haven't received yet, or 60 days for services already received.
What to include with your appeal:
- A written appeal statement from you explaining why coverage should be approved and why the denial was wrong
- The updated Letter of Medical Necessity from your doctor
- Copies of relevant lab results (HbA1c, lipid panel, blood pressure readings)
- Documentation of prior weight loss attempts
- Any relevant published studies or clinical guidelines (your doctor can help identify these)
- The denial letter itself
Send everything certified mail or via a method that gives you a confirmation of delivery. Keep copies of everything you submit. If you're filing online through your insurer's portal, take screenshots.
One tactic worth requesting at this stage: a peer-to-peer review. This is a direct call between your doctor and the insurer's medical director who reviewed your claim. Many insurers will grant this on request, and a doctor-to-doctor conversation about your specific case often carries more weight than paperwork alone. Your prescriber's office needs to request this, not you, so ask them to initiate it.
Step 4: Request an Expedited Appeal If Your Situation Is Urgent
A standard internal appeal is decided within 30 days when it is for a medication you have not received yet, or up to 60 days for care you already paid for. If waiting even that long would seriously jeopardize your health, you can request an expedited (urgent) appeal, and the insurer must respond within 72 hours.
What counts as urgent? Your doctor needs to certify in writing that the standard timeline would cause serious harm given your medical condition. This is more applicable for patients with severe obesity-related complications, uncontrolled type 2 diabetes, or significant cardiovascular risk factors where delay in treatment is genuinely dangerous. A general desire to start medication faster doesn't meet the threshold. Ask your doctor honestly whether your case qualifies.
Step 5: External Appeal or State Insurance Commissioner
If your internal appeal is denied, you're not done. Federal law gives you the right to an external appeal, where an independent organization (not your insurer) reviews the decision. Your insurer must tell you how to request one in their final denial letter.
External appeals must generally be filed within 4 months of your internal appeal denial. An independent reviewer looks at the same documentation and can overturn your insurer's decision. This process takes up to 45 days for standard reviews (72 hours for urgent).
Where to complain depends on how your employer's plan is funded. If the plan buys insurance from an insurance company (fully insured), your state's department of insurance can help. If your employer pays claims itself (self-funded), state insurance rules mostly do not apply. Contact the U.S. Department of Labor's Employee Benefits Security Administration at askebsa.dol.gov or 1-866-444-3272. Your plan documents or HR can tell you which kind you have. Some states also have consumer assistance programs that help patients navigate exactly this situation at no charge.
While You're Appealing: Your Alternatives
Appeals take time. If you want to start treatment while the process plays out, here are real options.
Manufacturer savings programs. Novo Nordisk offers a savings card that brings Wegovy down to as little as $25 per month for commercially insured patients whose plan covers it, up to $100 in savings per month. It requires being 18 or older, a valid prescription, and commercial (not Medicare, Medicaid, or other government) insurance. If you are uninsured or your plan excludes Wegovy, NovoCare's self-pay pharmacy is usually cheaper than a retail pharmacy, around $349 per month with a lower introductory price on your first fills. Eli Lilly's Zepbound savings card works the same way, as little as $25 per month for commercially insured patients whose plan covers it; without coverage, its LillyDirect self-pay starts at $299 per 28-day supply for the 2.5 mg dose, with higher doses priced higher (checked September 2026). Check the manufacturer websites for current terms, since these programs change often.
Cash-pay weight loss clinics. Many GLP-1 clinics offer semaglutide or tirzepatide programs in the $200-$500 per month range, bundled with provider visits and monitoring. That's substantially below the list price of brand-name Wegovy, around $1,350 per month without insurance. Search the clinic directory to find providers near you and compare pricing. (See our guide to finding affordable GLP-1 clinics.)
Compounded semaglutide and tirzepatide. Patient-specific compounding may still occur under section 503A when federal requirements are met, but pharmacies generally cannot regularly produce copies of commercially available GLP-1 drugs. The FDA has also proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk substances available to 503B outsourcing facilities; as of September 2026, that proposal has not been finalized. Compounded medications can cost less than brand-name versions, but they are not FDA-approved and quality varies by pharmacy. Discuss the risks and benefits with your doctor before going this route. Our guide on compounded vs. brand-name semaglutide explains the trade-offs.
Tips That Make a Real Difference
Get everything in writing. Every call with your insurer should be followed up with a written summary you send to them, confirming what was discussed. Verbal commitments from insurance companies don't hold up.
Keep a dedicated folder (physical or digital) for everything related to the appeal: denial letters, LMN drafts, submitted documents, certified mail receipts, call logs. You may need any of it at any stage.
Don't miss deadlines. The 180-day window to file an internal appeal sounds generous, but it goes fast when you're waiting on doctor paperwork. Set a calendar reminder for 90 days out as a hard checkpoint.
Consider a patient advocate. Some nonprofit organizations and patient advocacy groups help people navigate GLP-1 insurance denials. The Obesity Action Coalition is one resource that offers tools and support for patients dealing with coverage barriers.
Talk to your doctor about your specific situation before starting any new medication or changing your treatment plan.
Frequently Asked Questions
Standard internal appeals must be resolved within 30 days (for medications not yet received) or 60 days (for services already received), by law under the ACA. Expedited appeals, for urgent medical situations, must be resolved within 72 hours. External appeals take up to 45 days for standard reviews. The full process from internal denial to external review can take 3-4 months if every level is exhausted.
Step therapy means your plan requires you to try a less expensive treatment first before approving a GLP-1 medication. The specific requirement varies by plan, but it might mean documenting 3-6 months of a supervised diet program, or a trial of an older weight loss medication. Ask your insurer exactly what's required. If you've already tried and failed other interventions, document them carefully and have your doctor include that history in the Letter of Medical Necessity. Some states have step therapy override laws that can help if the required step is medically inappropriate for you.
Yes, though the path is harder. A blanket formulary exclusion means the drug class isn't covered under your plan, not just that your individual request was denied. You can still appeal on medical necessity grounds, especially if you have a cardiovascular disease diagnosis (semaglutide's cardiovascular benefits from the SELECT trial are making this argument stronger). If the internal appeal fails, an external reviewer or state insurance commissioner may still find the exclusion doesn't apply given your specific circumstances. It's also worth asking your employer's HR department whether the plan can be amended during the next enrollment period.
Possibly, but only if you have type 2 diabetes. Ozempic is FDA-approved for diabetes, not weight loss. If your primary need is weight management and you don't have a diabetes diagnosis, insurers will usually deny Ozempic for the same reason they deny Wegovy: the indication doesn't match your diagnosis. If you do have type 2 diabetes, Ozempic coverage is more likely. Your doctor can advise on whether your medical history supports a diabetes-indication prescription. See our comparison of Ozempic vs. Wegovy for more on how insurers treat the two differently.
A GLP-1 denial is aggravating, but treating it as the starting point of a process, not the end of one, changes how you approach it. Most people who get approved on appeal did so because they came back with better documentation, not because they argued louder. Work with your doctor, respond to the specific denial reason, and don't miss your deadline.
Find a GLP-1 clinic near you that can help navigate prior authorization and appeals. Many clinics deal with insurance companies every day and know exactly what documentation each major insurer wants to see. You can also check GLP-1 insurance coverage by your plan type before your next appointment.
Correction (September 2, 2026): Removed unsupported appeal-success estimates that conflated prior-authorization and claims-denial data; updated compounding and manufacturer-savings information from current primary sources.